Background: Early in the coronavirus disease 2019 (COVID-19) pandemic, hydroxychloroquine (HCQ) drew substantial attention as a potential COVID-19 treatment...
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
DSX is faster, more user-friendly, and scalable for high-performance computing
Plug n’ Play PBBM
The GastroPlus Plug n' Play PBBM Packages
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
Initiates first steps in updated capital allocation strategy
What’s New in GastroPlus® v9.8.3?
Learn about the new and improved functionality to drive advances to PBBM/PBPK applications from discovery through post-approval.
GastroPlus® Additional Dosage Routes Brochure
Trust Our Gut... and Model Everywhere!
Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging
Basmisanil, is a lipophilic drug substance, exhibiting poor solubility and good permeability (BCS class 2). A validated physiologically based biopharmaceutics model (PBBM)...
Review and Chemoinformatic Analysis of Ferroptosis Modulators with a Focus on Natural Plant Products
Ferroptosis is a regular cell death pathway that has been proposed as a suitable therapeutic target in cancer and neurodegenerative diseases.
Oral administration of VDAC1-derived small molecule peptides increases circulating testosterone levels in male rats
Cholesterol is the precursor of all steroid hormones, and the entry of cholesterol into the mitochondria is the rate-limiting step of steroidogenesis.
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
Total revenue of $12 million; Diluted Earnings Per Share (EPS) of $0.06; Both in line with fiscal 2023 guidance and Q1 expectations for revenue seasonality shift.
Provides capital allocation strategy update focusing on corporate development activities, $50 million share repurchase program, and internal investment